IN THE UNITED STATES PATENT AND TRADMARK OFFICE

Applicants: Pratt, et al.

Serial No.: 10/699,513

Filed: October 31, 2003

Title: ANTI-INFECTIVE AGENTS

Case No.: 6998US02

Group Art No.: (not yet assigned)

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450 on:

Date of Deposit: January 28, 2004

Tanva Parent

Date

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled ANTI-INFECTIVE AGENTS are the following:

- 1. Information Disclosure Statement;
- 2. Form PTO 1449, in duplicate;
- 3. Reference as cited on PTO 1449 (15 reference); and
- 4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

ABBOTT LABORATORIES

Customer Number 23492 Telephone: (847) 935-7835

Facsimile: (847) 938-2623

Respectfully submitted,

Pratt, et_al,

Kalim S. Fuzail

Registration No. 45,805

Attorney for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Pratt, et al.

Serial No.: 10/699,513

Filed: October 31, 2003

Title: ANTI-INFECTIVE AGENTS

Case No.: 6998US02

Group Art No.: (not yet assigned)

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 on:

Date of Deposit: January 28, 2004

Tanya Parent

Dat

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

ABBOTT LABORATORIES

Customer Number 23492 Telephone: (847) 935-7835

Facsimile: (847) 938-2623

Respectfully submitted,

Pratt, et al

Kalim S. Fuzail

Registration No. 45,805

Attorney for Applicants

Form PTO - 1449 (Modified)

DATE: January 28, 2004 SHEET _1_ of _1_

FORM PTO-I (Modified)	449 U.S. DEPARTMENT OF COMMENT OF ICE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO. 6998.US.02			SERIAL NO. 10/699,513		
	IN	FORMATION DISCLOS		APPLICANT(S)				120.055,620		
	ST	Pratt, et al.								
•					FILING DATE GROUP					
(Use several sheets if necessary)					October 31, 2003			Not yet assigned		
37 CFR 1.98 (b))									
			U.S.PATEN	T DOO	CUMENTS	3				
EXAMINER		DATENTE MARKET	ISSUE	T ,,,	VENTOR	GI AGG	SUB CLASS		FILING	
INITIAL	Al	PATENT NUMBER 3,133,918	DATE 05/19/64	IN	VENTOR	CLASS	CLA	455	DAT	E
	A2	3,291,794	12/13/66							
	A3	3,499,082	03/03/70							
	A4	5,378,704	01/03/95	Welle	er					
	EOD	EIGN PATENT O	n blibi ich	ED EO	DEICN D	ATENT A	DDI	ICATI	ON	
	FUR	DOCUMENT I	PUBLIC-ATIO		COUNTRY O			SUB	ON LTRA	NS-
		NUMBER	DATE	PA	TENT OFFI			CLASS	LATION YES NO	
	ВТ	386435		CH			+		X	NO
	B2	0 618 209	23.12.98	EP	***		-		X	<u> </u>
	B3	885950		GB					ļ. <u>.</u>	ļ
			15 11 01	ı						
	B4	01/85172	15.11.01	W						
	B5	02/98424	12.12.02	W)					
	В6	03/37262	08.05.03	W)					
	В7	03/59356	24.07.03	W)					
	L	1								L
	~ 11	OTHER DOCUM							1 11 1	
	Cl	Dhanak et al., "Ident of the Hepatitis C Vi Chemistry 277(41);	rus RNA-depe	ndent R						rs
	C2	Dhanak et al., "Ident of the Heptitis C Vir	tification and Bus RNA-Deper	iologica ident Rl	NA Polymer	ase," 9 th Ir	iternat	tional M	eeting	
	C2	HCV and Related V								
	C3	McHutchison, The American Association for the Study of Liver Diseases, Hepatitis Single Topic Conference: Hepatitis C New Drug and Clinical Trials Development: Promises and Pitfalls. Abstract #5; February 27-March 1, 2003, Chicago, IL								
	C4	Ukrainets et al., "4-Hydroxy-2-Quinolones. 42*. Synthesis and biological Activity of I-R-2-Oxo-3-(2H-1,2,4-Benzothiadiazine-1,1-Dioxid-3-YI)-4-Hydroxyquinolines,"								
		R-2-Oxo-3-(2H-1,2, Chemistry of Hetero					oxyqu	inolines	,´´	
EXAMINER		1 3.1011121.7 01 1101010	-,		TE CONSII					